Limitations, agreements, and source contact

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia · Source last updated 2020-05-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details

Must obtain prior Sponsor approval.

pi Sponsor Employee

false

restriction Type

OTHER

restrictive Agreement

true

point Of Contact

email

resultsreportingcoordinator@childrensoncologygroup.org

organization

Children's Oncology Group

phone

626-447-0064

title

Results Reporting Coordinator

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice